Form 4: Natures Sunshine Exec Vests Shares, Hits EBITDA Target

Natures Sunshine Products' EVP & President, Europe, Bryant J. Yates, vested performance-based restricted stock units after the company achieved a key Adjusted EBITDA milestone.

Summary

• Bryant J. Yates, EVP & President, Europe, of Natures Sunshine Products Inc. (NATR), reported changes in beneficial ownership of common shares.
• On November 4, 2025, Yates acquired 1,224 common shares from a July 21, 2022, performance-based restricted stock unit (RSU) grant.
• This vesting occurred because the company achieved an adjusted EBITDA milestone of $46.2 million over a rolling 12-month period.
• Also on November 4, 2025, Yates acquired 2,716 common shares from an April 20, 2023, performance-based RSU grant, also due to the $46.2 million adjusted EBITDA milestone achievement.
• In both cases, half of the target vested upon achievement, with the remaining half set to vest one year later.
• To cover taxes upon vesting, 354 shares and 780 shares of NATR common stock were disposed of at a price of $13.75 per share, based on the closing price on November 4, 2025.
• Following these transactions, Yates beneficially owns 100,304 common shares.

Sentiment

Score: 7

Explanation: The filing indicates successful achievement of a key financial performance milestone (Adjusted EBITDA) which led to executive equity vesting. This suggests positive operational performance and strong alignment between executive incentives and company results. The share dispositions are routine tax withholdings.

Positives

• Achievement of a $46.2 million Adjusted EBITDA milestone, indicating strong operational performance.
• Vesting of performance-based restricted stock units for a key executive, aligning management incentives with company performance.
• The executive's increased beneficial ownership (net of tax withholding) demonstrates continued alignment with shareholder interests.

Negatives

• Disposition of shares to cover tax obligations, which is a common occurrence but reduces the executive's immediate direct holdings.

Future Outlook

Half of the performance-based restricted stock units that vested on November 4, 2025, are scheduled to vest one year following the achievement of the Adjusted EBITDA milestone, indicating future share grants contingent on continued employment.

Industry Context

This insider transaction reflects a standard executive compensation practice where performance-based equity awards vest upon the achievement of specific financial targets, a common mechanism in the health and wellness or direct selling industries to align executive incentives with shareholder value creation.

Comparison to Industry Standards

• The use of Adjusted EBITDA as a performance metric for executive compensation is a common practice across various industries, including consumer goods and direct selling, aligning executive incentives with operational profitability.
• The specific $46.2 million target would need to be benchmarked against peer companies in the health and wellness sector like Herbalife Nutrition (HLF) or USANA Health Sciences (USNA) to assess its relative ambition and achievement difficulty, but the successful vesting indicates the target was met.

Stakeholder Impact

• Shareholders: The achievement of the Adjusted EBITDA milestone and the vesting of performance-based equity for a key executive could be viewed positively, indicating management's successful execution against financial targets and alignment of interests.
• Employees: The successful vesting of performance-based awards for an executive may signal a healthy company performance environment.

Next Steps

• The remaining half of the performance-based restricted stock units from the July 21, 2022, and April 20, 2023, grants are scheduled to vest one year after the November 4, 2025, milestone achievement date.

Key Dates

Recommendation

This Form 4 filing primarily reports routine insider transactions related to the vesting of performance-based restricted stock units and subsequent tax withholdings. While the achievement of the Adjusted EBITDA milestone is a positive indicator of operational performance, it is historical and already reflected in the company's financial statements. The filing itself does not introduce new material information that would significantly alter the investment thesis or warrant a change from a 'hold' position, assuming the company's fundamentals remain consistent with prior disclosures.

Keywords

Natures Sunshine Products, NATR, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, EBITDA, Executive Compensation, Beneficial Ownership, Bryant J. Yates